Advanced Enzyme Technologies Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹172Cr
- +1.8% YoY
- −7% QoQ
- Net profit
- ₹43Cr
- +10.3% YoY
- −4.4% QoQ
- Margin
- 29%
- −4 pp YoY
- −4 pp QoQ
Guidance rank: #81 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.
From Advanced Enzyme Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22).
- Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22).
- There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24).
- Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19).
- The company aims to expand into new geographical and application markets, especially in healthcare and biochemical processing, to utilize capacity and grow revenues (Page 17).
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major CapEx planned for the current fiscal year except for R&D-related investments.
- Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year.
- Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation.
- Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion.
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year.
- The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes.
- There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders.
2 more points from Advanced Enzyme Technologies Ltd's call on order book
Create a free account to keep reading this call
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Advanced Enzyme Technologies Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 172 | 169 | +1.8% | 185 | -7% |
| Operating profit (EBITDA) | 49 | 55 | -10.9% | 60 | -18.3% |
| Operating margin | 29% | 33% | -4 pp | 33% | -4 pp |
| Profit before tax | 58 | 53 | +9.4% | 60 | -3.3% |
| Net profit (PAT) | 43 | 39 | +10.3% | 45 | -4.4% |
| EPS (₹) | 3.80 | 3.37 | +12.8% | 3.87 | -1.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹215 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q3 FY26 results?
The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
No major CapEx planned for the current fiscal year except for R&D-related investments.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
